



ASX Announcement

7 September 2022

Atomo FY22 Results Presentation

Atomo Diagnostics Limited (ASX:AT1) released its FY22 Results on 25 August 2022.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly and CFO, Will Souter, will be held on Thursday, 8 September 2022 at 11.00 am (AEST).

To access the webinar please pre-register via the following link:

https://us02web.zoom.us/webinar/register/WN_XN_I6VLoR9W7Oafxlo4cdQ

~ ENDS ~

For more information, please contact:

John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279

Investor Queries
investorqueries@atomodiagnostics.com

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com